Asia
In the latest joint effort, Lee’s Pharm will pair its PD-L1 candidate with icaritin.
Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.
Share prices for Protalix are up more than 3 percent this morning after the company reported positive results from its Phase I/II open label extension trial of pegunigalsidase alfa, PRX-102, for the treatment of Fabry disease.
News of the layoffs comes hard on the heels of the company’s credit rating having been cut to junk status by Fitch Rating.
A look at the 19 spine-related medical devices the FDA cleared in October.
Zensun Science & Technology raised $76M from a group of investors led by SDIC Venture Capital Management, which contributed half of the funding itself.
Peptidream has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.
Bloomberg noted that Takeda’s CEO is looking at making Takeda a nimble company, but one with a deeply entrenched R&D focus.
Teva’s stock jumped as investors get more hopeful about the future.
In 2015 and 2016, the FDA found 134 instances when drugs or active ingredients failed initial testing but the company chose to override the results.
PRESS RELEASES